Skip to main content

Advertisement

Table 1 Baseline characteristics by treatment group and study at day 0. Means are arithmetic. CQ = chloroquine, SP = sulphadoxine-pyrimethamine, AS1 = 1-dose artesunate, AS-3 = 3-dose artesunate, AL = artemether-lumefantrine (Coartem), AQ = amodiaquine.

From: Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials

Study & country Treatment N Parasitology follow up days (bold = transmission experiment) Mean age (years) Mean asexual parasite density/μl Mean slide- positive gametocyte prevalence (%) Mean gametocyte density/μl
1. Gambia Targett 2001 [22] CQ 135 4, 7,14,28 5.9 80,886 2.5 33
  SP 277   6.0 73,742 5.6 13
  SP-AS1 113   6.2 23,147 10.7 10
  SP-AS3 74   6.3 26,567 13.4 88
  all 599   6.0 59,581 6.9 26
2. Gambia Targett 2001 [22] SP 101 7,14 4.4 28,684 6.0 31
  SP-AS3 404   4.8 27,738 8.0 127
  all 505   4.7 27,927 7.6 107
3. Gambia Drakeley 2004 [20] CQ 129 3, 7,14,28 4.7 64,329 20.2 10
  CQ-AS 386   4.8 66,593 20.2 22
  all 515   4.8 66,026 20.2 19
4. Gambia Hallett 2006 [13] CQ 125 3, 7, 10, 14,28 4.5 63,640 21.6 30
  SP 180   4.5 58,128 23.2 47
  CQ-SP 193   4.6 79,900 19.2 37
  all 498   4.6 68,009 21.2 39
5. Gambia Sutherland 2005 [21] CQ-SP 89 7,14,28 4.3 56,444 4.5 5
  AL 400   4.4 57,550 6.3 9
  (Coartem)       
  all 489   4.3 57,347 6.0 9
6. Kenya Bousema 2006 [19] SP 152 3,7, 14,28 3.4 19,044 20.9 7
  SP-AQ 127   2.9 20,578 22.3 8
  SP-AS3 174   3.2 21,620 24.4 8
  AL (Coartem) 75   4.0 21,178 24.6 6
  all 528   3.3 20,565 22.9 7